EMBER-4

Name No. For Patients with Purpose
EMBER-4 24-07

Estrogen receptor positive (ER+), human epidermal receptor 2 negative (HER2-) early-stage, resected, invasive breast cancer without evidence of distant metastasis.

To measure how well imlunestrant works compared to standard hormone therapy in patients with early-stage breast cancer that is ER+ and HER2-.


Exosomes in TNBC (TS)

Name No. For Patients with Purpose
Exosomes in TNBC (TS) 22-21

Early or metastatic triple negative breast cancer (TNBC)

The main purpose of this study is to profile exosomes isolated from the plasma of 40 women diagnosed with TNBC during routine treatment and follow up in the oncology clinic using Nanoparticle tracking analysis (NTA) and Raman/infra-red spectroscopy.


UCARE (TS)

Name No. For Patients with Purpose
UCARE (TS) 24-21

Female patients diagnosed with stage I-III breast cancer.

The main purpose of the study is to evaluate pathways for identifying, managing, and overcoming side effects of cancer therapies that can negatively impact quality-of-life and overall outcomes for women during and after cancer treatment.


Wavelia

Name No. For Patients with Purpose
Wavelia 24-22

Female patients with an investigator-assessed discrete breast abnormality of size > 1cm.

The main purpose of this study is to determine whether a microwave imaging system (Wavelia #2) can be used for the detection of breast cancer.


EXPERT

Name No. For Patients with Purpose
EXPERT 19-03

Patients with luminal A early breast cancer who had breast conserving surgery and endocrine therapy

The purpose of this study is to see whether a genomic test (looking at specific genes) of breast cancer tissue can be used to select women who can safely avoid radiation therapy because they have a low risk of the cancer coming back.


SHAMROCK study

Name No. For Patients with Purpose
SHAMROCK study 22-01

Patient with newly diagnosed early stage HER2-positive breast cancer with tumour size larger than 2cm

The goal of this study is to investigate how effective neoadjuvant treatment with trastuzumab deruxtecan is for patients with early stage locally advanced HER2 positive breast cancer.


EPIK-B5

Name No. For Patients with Purpose
EPIK-B5 21-32

HR-positive, HER2-negative advanced breast cancer with a PIK3CA mutation who progressed or relapsed on or after treatment with an AI plus a CDK4/6 inhibitor.

The purpose of this study is to obtain more comprehensive data on the efficacy and safety of alpelisib (BYL719) in combination with fulvestrant compared with placebo plus fulvestrant in men or postmenopausal women with HR-positive, HER2-negative advanced breast cancer with a PIK3CA mutation who progressed or relapsed on or after treatment with an AI plus a CDK4/6 inhibitor.


Proteomics / Molecular Breast

Name No. For Patients with Purpose
Proteomics / Molecular Breast 09-07

Breast cancer

The purpose of this trial is to examine the function of different genes and proteins, previously identified to be of interest, and identify new ones, as well as the means by which they interact and differ between cancer cells.